GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (LTS:0K1R) » Definitions » Cyclically Adjusted PS Ratio

Viridian Therapeutics (LTS:0K1R) Cyclically Adjusted PS Ratio : 0.14 (As of May. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Viridian Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-05-10), Viridian Therapeutics's current share price is $13.95. Viridian Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $98.22. Viridian Therapeutics's Cyclically Adjusted PS Ratio for today is 0.14.

The historical rank and industry rank for Viridian Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0K1R' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.18   Max: 0.27
Current: 0.14

During the past years, Viridian Therapeutics's highest Cyclically Adjusted PS Ratio was 0.27. The lowest was 0.10. And the median was 0.18.

LTS:0K1R's Cyclically Adjusted PS Ratio is ranked better than
96.5% of 514 companies
in the Biotechnology industry
Industry Median: 5.615 vs LTS:0K1R: 0.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viridian Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $98.22 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viridian Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Viridian Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Cyclically Adjusted PS Ratio Chart

Viridian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.21 0.22

Viridian Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.20 0.20 0.14 0.22

Competitive Comparison of Viridian Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Viridian Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Cyclically Adjusted PS Ratio falls into.



Viridian Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Viridian Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.95/98.22
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Viridian Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.001/129.4194*129.4194
=0.001

Current CPI (Dec. 2023) = 129.4194.

Viridian Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 64.176 99.695 83.311
201406 424.667 100.560 546.544
201409 72.278 100.428 93.143
201412 38.529 99.070 50.332
201503 24.808 99.621 32.228
201506 20.971 100.684 26.956
201509 13.917 100.392 17.941
201512 14.021 99.792 18.184
201603 17.042 100.470 21.952
201606 18.208 101.688 23.173
201609 18.521 101.861 23.532
201612 15.429 101.863 19.603
201703 0.600 102.862 0.755
201706 0.503 103.349 0.630
201709 1.134 104.136 1.409
201712 0.801 104.011 0.997
201803 2.709 105.290 3.330
201806 1.080 106.317 1.315
201809 0.461 106.507 0.560
201812 0.231 105.998 0.282
201903 0.181 107.251 0.218
201906 1.217 108.070 1.457
201909 0.335 108.329 0.400
201912 0.408 108.420 0.487
202003 0.273 108.902 0.324
202006 0.047 108.767 0.056
202009 0.000 109.815 0.000
202012 0.014 109.897 0.016
202103 0.229 111.754 0.265
202106 0.134 114.631 0.151
202109 0.019 115.734 0.021
202112 0.009 117.630 0.010
202203 0.008 121.301 0.009
202206 0.009 125.017 0.009
202209 0.035 125.227 0.036
202212 0.003 125.222 0.003
202303 0.002 127.348 0.002
202306 0.002 128.729 0.002
202309 0.002 129.860 0.002
202312 0.001 129.419 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viridian Therapeutics  (LTS:0K1R) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Viridian Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics (LTS:0K1R) Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 401, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Viridian Therapeutics (LTS:0K1R) Headlines

No Headlines